Elanco (ELAN) CAO reports RSU grants and tax-withholding share disposal

Rhea-AI Filing Summary

Elanco Animal Health chief accounting officer James M. Meer reported equity compensation and related tax withholding transactions in company common stock. He received grants classified as restricted stock units covering 9,596 shares and 5,209 shares, both at a stated price of $0.00 per share. A separate transaction disposed of 4,787 shares at $26.40 per share to satisfy tax liability by delivering shares. The restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.

Insider Trade Summary

Net Buyer: 10,018 shares

Net Buy 3 txns

Insider Meer James M

Role CHIEF ACCOUNTING OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	9,596	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	4,787	$26.40	$126K
Grant/Award	Common Stock	5,209	$0.00	$0.00

Holdings After Transaction: Common Stock — 68,121 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/03/2026 - 07:19 PM Learn about SEC filing dates

FAQ

What insider activity did Elanco (ELAN) report for James M. Meer?

Elanco reported that chief accounting officer James M. Meer received equity awards and had shares withheld for taxes. The Form 4 lists restricted stock unit grants and a tax-withholding share disposition, all involving company common stock on March 1, 2026.

How many Elanco (ELAN) shares were granted to James M. Meer?

James M. Meer reported two grant or award acquisitions in Elanco common stock: 9,596 shares and 5,209 shares. These are classified as restricted stock unit awards with a stated acquisition price of zero, reflecting equity-based compensation rather than open-market purchases.

What is the vesting schedule for James M. Meer’s Elanco (ELAN) RSUs?

The restricted stock units vest in three equal installments over three years. One‑third vests on March 1, 2027, another third on March 1, 2028, and the remaining portion vests on March 1, 2029, subject to standard award conditions.

Did James M. Meer sell Elanco (ELAN) shares in the open market?

The filing shows a disposition of 4,787 Elanco shares coded as “F,” indicating shares used to pay tax liability or exercise costs. This represents tax withholding by delivering securities, not a discretionary open‑market sale transaction.

What share price applied to the Elanco (ELAN) tax-withholding transaction?

The tax-withholding disposition for James M. Meer used a share value of $26.40 per Elanco common share. In this transaction, 4,787 shares were delivered to satisfy tax obligations related to his equity awards rather than being sold for personal cash proceeds.

What role does James M. Meer hold at Elanco (ELAN)?

James M. Meer serves as chief accounting officer at Elanco Animal Health. The Form 4 filing reflects his equity compensation activity in company common stock, including new restricted stock unit grants and shares withheld to cover associated tax liabilities.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meer James M

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		9,596	A	$0	67,699	D
Common Stock	03/01/2026		F		4,787	D	$26.4	62,912	D
Common Stock	03/01/2026		A		5,209(1)	A	$0	68,121	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

	/s/ Amy C. Seidel, Attorney-in-Fact for James M. Meer	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.